Abeona Therapeutics Inc (ABEO)

Currency in USD
7.1300
-0.1000(-1.38%)
Closed·
7.2700+0.1400(+1.96%)
·
ABEO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
ABEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.11007.5401
52 wk Range
3.93287.5401
Key Statistics
Prev. Close
7.23
Open
7.35
Day's Range
7.11-7.5401
52 wk Range
3.9328-7.5401
Volume
1.15M
Average Volume (3m)
958.43K
1-Year Change
42.6%
Book Value / Share
3.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.0714
Upside
+181.51%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Abeona Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Abeona Therapeutics Inc Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Employees
136

Abeona Therapeutics Inc Earnings Call Summary for Q2/2025

  • Abeona Therapeutics reported Q2 2025 EPS of $1.71, exceeding -$0.38 forecast, with $400,000 revenue and $108.8M net income
  • FDA approval of ZevaSkin in April 2025 boosted market confidence; stock surged 10.21% post-earnings to $7.23
  • Company anticipates profitability by early 2026, plans to expand manufacturing capacity to 10 patients/month by mid-2026
  • Exploring international opportunities in EU and Japan; CEO highlights ZivaSkin as first autologous cell-based gene therapy for RDEB
  • Analysts inquired about patient identification and international expansion plans during Q&A session
Last Updated: 15/08/2025, 12:06
Read Full Transcript

Compare ABEO to Peers and Sector

Metrics to compare
ABEO
Peers
Sector
Relationship
P/E Ratio
6.4x−3.0x−0.5x
PEG Ratio
0.04−0.020.00
Price/Book
2.2x1.5x2.6x
Price / LTM Sales
911.9x7.5x3.3x
Upside (Analyst Target)
180.5%203.4%40.3%
Fair Value Upside
Unlock−2.6%5.1%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.0714
(+181.51% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
1.71 / -0.38
Revenue / Forecast
400.00K / --
EPS Revisions
Last 90 days

ABEO Income Statement

People Also Watch

2.140
VOR
+8.08%
17.82
BEAM
+1.08%
3.05
RCKT
+0.66%
48.080
ASTS
-0.87%
285.66
BIO
-0.54%

FAQ

What Stock Exchange Does Abeona Therapeutics Trade On?

Abeona Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Abeona Therapeutics?

The stock symbol for Abeona Therapeutics is "ABEO."

What Is the Abeona Therapeutics Market Cap?

As of today, Abeona Therapeutics market cap is 364.74M.

What Is Abeona Therapeutics's Earnings Per Share (TTM)?

The Abeona Therapeutics EPS (TTM) is 1.15.

When Is the Next Abeona Therapeutics Earnings Date?

Abeona Therapeutics will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is ABEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Abeona Therapeutics Stock Split?

Abeona Therapeutics has split 4 times.

How Many Employees Does Abeona Therapeutics Have?

Abeona Therapeutics has 136 employees.

What is the current trading status of Abeona Therapeutics (ABEO)?

As of 16 Aug 2025, Abeona Therapeutics (ABEO) is trading at a price of 7.13, with a previous close of 7.23. The stock has fluctuated within a day range of 7.11 to 7.54, while its 52-week range spans from 3.93 to 7.54.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.